El año pasado, Smith & Nephew PLC generó 1.07B USD en su segmento con mejor rendimiento, Sports Medicine Joint Repair. United States of America realizó la mayor aportación, representando 3.31B USD el año pasado. Para el último trimestre, Smith & Nephew PLC reportó unos ingresos de 300.00M USD para el periodo finalizado el 2026-06-27, procedentes del segmento con mejor rendimiento, Advanced Wound Care. United States of America aportó los mayores ingresos, alcanzando los 816.00M USD.

Por negocio

Ingresos operativos

Proporción

Anual

Anual

Trimestral

Sports Medicine Joint Repair

Knee Implants

Advanced Wound Care

Trauma & Extremities

Arthroscopic Enabling Technologies

Hip Implants

Advanced Wound Bioactives

Advanced Wound Devices

ENT (Ear, Nose and Throat)

Other Surgical Businesses

FY2025

FY2024

FY2023

FY2022

FY2021

FY2020

FY2019

FY2018

Sports Medicine Joint Repair

1.07B(17.31%)

982.00M(16.90%)

945.00M(17.03%)

870.00M(16.68%)

839.00M(16.10%)

710.00M(15.57%)

794.00M(15.45%)

697.00M(14.21%)

Knee Implants

1.01B(16.40%)

947.00M(16.30%)

940.00M(16.94%)

899.00M(17.24%)

876.00M(16.81%)

822.00M(18.03%)

1.04B(20.28%)

1.02B(20.74%)

Advanced Wound Care

766.00M(12.43%)

735.00M(12.65%)

725.00M(13.07%)

712.00M(13.65%)

731.00M(14.03%)

647.00M(14.19%)

714.00M(13.90%)

740.00M(15.09%)

Trauma & Extremities

649.00M(10.53%)

608.00M(10.46%)

564.00M(10.16%)

543.00M(10.41%)

576.00M(11.05%)

460.00M(10.09%)

488.00M(9.50%)

493.00M(10.05%)

Arthroscopic Enabling Technologies

647.00M(10.50%)

632.00M(10.88%)

588.00M(10.60%)

567.00M(10.87%)

590.00M(11.32%)

517.00M(11.34%)

591.00M(11.50%)

600.00M(12.23%)

Hip Implants

641.00M(10.40%)

619.00M(10.65%)

599.00M(10.79%)

584.00M(11.20%)

612.00M(11.74%)

567.00M(12.43%)

613.00M(11.93%)

613.00M(12.50%)

Advanced Wound Bioactives

621.00M(10.07%)

581.00M(10.00%)

553.00M(9.97%)

520.00M(9.97%)

496.00M(9.52%)

431.00M(9.45%)

424.00M(8.25%)

320.00M(6.53%)

Advanced Wound Devices

406.00M(6.59%)

365.00M(6.28%)

328.00M(5.91%)

280.00M(5.37%)

269.00M(5.16%)

232.00M(5.09%)

242.00M(4.71%)

215.00M(4.38%)

ENT (Ear, Nose and Throat)

220.00M(3.57%)

210.00M(3.61%)

196.00M(3.53%)

153.00M(2.93%)

131.00M(2.51%)

106.00M(2.32%)

151.00M(2.94%)

--(--)

Other Surgical Businesses

136.00M(2.21%)

131.00M(2.25%)

111.00M(2.00%)

87.00M(1.67%)

92.00M(1.77%)

68.00M(1.49%)

79.00M(1.54%)

209.00M(4.26%)

Por región

Ingresos operativos

Proporción

Anual

Anual

Trimestral

United States of America

Other Established Markets

Emerging &internatiuonal market

United Kingdom

China

Other

Established Markets

FY2025

FY2024

FY2023

FY2022

FY2021

FY2020

FY2019

FY2018

FY2017

FY2016

FY2015

FY2014

FY2013

FY2012

FY2011

United States of America

3.31B(53.63%)

3.12B(53.75%)

2.98B(53.69%)

2.76B(53.00%)

2.66B(51.00%)

2.34B(51.29%)

2.55B(49.65%)

2.35B(48.00%)

2.33B(48.94%)

2.30B(49.24%)

2.22B(47.84%)

2.01B(43.58%)

1.86B(42.79%)

1.65B(39.91%)

1.76B(41.12%)

Other Established Markets

1.48B(24.03%)

1.27B(21.88%)

1.14B(20.45%)

999.00M(19.16%)

1.10B(21.05%)

966.00M(21.18%)

1.08B(21.08%)

1.48B(30.22%)

--(--)

1.71B(41.24%)

1.77B(41.43%)

Emerging &internatiuonal market

1.00B(16.27%)

980.00M(16.87%)

959.00M(17.28%)

947.00M(18.16%)

916.00M(17.57%)

771.00M(16.91%)

957.00M(18.63%)

857.00M(17.48%)

--(--)

677.00M(14.66%)

563.00M(12.94%)

483.00M(11.68%)

454.00M(10.63%)

United Kingdom

246.00M(3.99%)

226.00M(3.89%)

201.00M(3.62%)

186.00M(3.57%)

189.00M(3.63%)

166.00M(3.64%)

211.00M(4.11%)

211.00M(4.30%)

244.00M(5.12%)

266.00M(5.70%)

301.00M(6.50%)

299.00M(6.48%)

293.00M(6.73%)

297.00M(7.18%)

291.00M(6.81%)

China

128.00M(2.08%)

210.00M(3.61%)

275.00M(4.96%)

319.00M(6.12%)

352.00M(6.75%)

318.00M(6.97%)

336.00M(6.54%)

--(--)

Other

--(--)

2.19B(45.94%)

2.10B(45.06%)

2.12B(45.66%)

--(--)

Established Markets

--(--)

1.63B(35.28%)

1.63B(37.53%)

--(--)